Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of $0.73 per share for the quarter. Halozyme Therapeutics has set its FY24 guidance at $3.55-3.90 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.07. The company had revenue of $195.88 million during the quarter, compared to the consensus estimate of $201.72 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. On average, analysts expect Halozyme Therapeutics to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Halozyme Therapeutics Trading Up 0.1 %
Shares of Halozyme Therapeutics stock traded up $0.06 during trading on Tuesday, hitting $55.53. The stock had a trading volume of 96,474 shares, compared to its average volume of 1,242,172. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The stock has a market cap of $7.07 billion, a PE ratio of 22.92, a PEG ratio of 0.57 and a beta of 1.27. Halozyme Therapeutics has a 12 month low of $32.83 and a 12 month high of $57.08. The firm’s fifty day simple moving average is $50.25 and its 200-day simple moving average is $42.79.
Insider Activity
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on HALO. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. JMP Securities dropped their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Benchmark upped their price target on Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Finally, The Goldman Sachs Group increased their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $58.38.
Check Out Our Latest Report on HALO
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
See Also
- Five stocks we like better than Halozyme Therapeutics
- Investing in Travel Stocks Benefits
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
- What is the Dogs of the Dow Strategy? Overview and Examples
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
- Top Biotech Stocks: Exploring Innovation Opportunities
- Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.